Ask the author session

We have all heard about the transformative impact of semaglutide on weight loss, but a groundbreaking new study suggests its benefits for the liver might be far more direct—and independent of the scale—than we ever imagined.

In our latest “Ask the Author” session, we sit down with Dr. González Rellán from the Lunenfeld Tanenbaum Research Institute to discuss her team’s recent publication in Cell Metabolism. Their research tackles a long-standing controversy in the field: Does semaglutide improve liver health simply because patients lose weight, or is there a direct hepatic mechanism at play?

👉 You can watch the full interview below — don’t miss it.

The “Weight-Independent” Breakthrough

Using innovative genetic mouse models, Dr. González Rellán and her team were able to dissociate weight loss from drug action. They discovered that semaglutide significantly improved liver inflammation and fibrosis even in mice that did not lose any weight.

The secret lies in a specific population of liver sinusoidal endothelial cells (LSECs) located in the pericentral region of the liver. These cells express the GLP-1 receptor, and the study proved that when these receptors are selectively removed, the liver-protective benefits of semaglutide vanish—even if the subject continues to lose weight.

Why This Matters for Patients

This discovery has profound implications for how we treat Metabolic Dysfunction-Associated Steatohepatitis (MASH). During the interview, Dr. González Rellán highlights two critical groups of patients who could benefit from these findings:

  • Non-responders: Patients who take GLP-1 agonists but do not experience substantial weight loss.
  • Lean MASH: Patients who already have a healthy weight but suffer from severe liver disease.

As Dr. González Rellán explains, “Weight loss alone may not fully capture the full therapeutic benefit of semaglutide”. This opens the door for new dosing strategies that focus on liver repair rather than just maximizing weight loss.

Watch the Full Interview

Are you ready to dive deeper into the transcriptomics and proteomics behind this discovery? Curious about how the ESSENCE trial clinical data aligns with these findings?

Click here to watch the full interview with Dr. González Rellán and learn how the intrahepatic GLP-1 receptor is orchestrating a new era of liver health.

Thank you to our sponsors